Advertisement

Topics

Latest "Vivos Therapeutics" News Stories - Page: 4

22:24 EDT 26th March 2019 | BioPortfolio

Here are the most relevant search results for "Vivos Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Vivos Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Vivos Therapeutics for you to read. Along with our medical data and news we also list Vivos Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Vivos Therapeutics Companies for you to search.

Showing "Vivos Therapeutics" News Articles 76–100 of 7,800+

Probably Relevant

e-Therapeutics (ETX) - Releasing hidden value

Edison Investment Research - Pharmaceutical & healthcare - e-Therapeutics: e-Therapeutics (ETX) has announced an update on its collaboration with C4X Discovery (C4XD) on novel interventions in Parkinson’s disease (PD). The PD collaboration started in May 2018 and combines the network-driven drug discovery (NDD) platform at ETX with the genetic information from C4XD’s platform. This has...


Finch Therapeutics’ C. Difficile infection drug gets breakthrough status

Microbial therapies developer Finch Therapeutics has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for its...Read More... The post Finch Therapeutics’ C. Difficile infection drug gets breakthrough status appeared first on Pharmaceutical Technology.

Roche to Acquire Gene Therapy Firm Spark Therapeutics for $4.3 Billion

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) today announced that they have entered into a definitive merger agreement for Roche to fully acquire Spark Therapeutics at a price of US$ 114.50 per share in an all-cash transaction. This corresponds to a total transaction value of approximately US$ 4.3 billion on …


e-Therapeutics (ETX) - The benefits of partnerships and cost control

Edison Investment Research - Pharmaceuticals & healthcare - e-Therapeutics: e-Therapeutics’ (ETX) FY19 results demonstrated continued financial prudence and its focus on partnering, out-licensing and non-dilutive financing. The FY19 operating loss was £5.1m, which is the same as our estimate. The cash outflow was £3.7m, resulting in a cash balance of £5.9m at the end of FY19. ...

Seelos Therapeutics Announces Successful Completion of its Merger with Apricus Biosciences

Seelos Therapeutics (Nasdaq:SEEL), a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders, announced today the completion of its previously disclosed merger with Apricus Biosciences. As quoted in the press release: The combined company changed ...

STAT Plus: Werewolf moves into a web of immunotherapy startups

No one seems to know where Werewolf Therapeutics got its name. But it’s clear where the new startup got its lab space and staff: Potenza Therapeutics.

STAT Plus: SQZ Therapeutics pushes forward with its method to squeeze drugs into cells

SQZ Therapeutics is working on a new way to get medicines into cells — and it's had a very busy fall.

This Day That Year: BioXcel Therapeutics

Shares of BioXcel Therapeutics Inc. (BTAI) are down nearly 47% from their all-time high of $14.79 recorded on July 10, 2018.

This Day That Year : Menlo Therapeutics

Shares of Menlo Therapeutics Inc. (MNLO) are down 86% from their 52-week high of $39.86 recorded on February 6, 2018.

Avenue Therapeutics, Inc. (ATXI) InvaGen Announces Acquisition Agreement with Avenue Therapeutics Conference Call (Transcript)

Smith & Nephew agrees to buy Osiris Therapeutics for $660m

Based in Columbia of Maryland, Osiris Therapeutics is engaged in the development, manufacturing and commercialization of regenerative medicine products such as skin, bone graft and articular cartilage substitutes. The post Smith & Nephew agrees to buy Osiris Therapeutics for $660m appeared first on Compelo Medical Devices - Latest industry news and analysis.

5 Top Weekly NASDAQ Biotech Stocks: Magenta Therapeutics Rises

Magenta Therapeutics, China SXT Pharmaceuticals, Genocea Biosciences, MeiraGTx Holdings and Equillium were last week's top gainers. The post 5 Top Weekly NASDAQ Biotech Stocks: Magenta Therapeutics Rises appeared first on Investing News Network.

FDA clears Fate Therapeutics’ stem cell therapy for an IND application

Fate Therapeutics has announced the US Food and Drug Administration (FDA) has allowed it to begin clinical investigation and submit...Read More... The post FDA clears Fate Therapeutics’ stem cell therapy for an IND application appeared first on Pharmaceutical Technology.

Why Pluristem Therapeutics believe that in cell therapy “the process is the product”

Karine Kleinhaus, Divisional Vice President, North America, Pluristem Therapeutics

Deals this week: CRISPR, Dragonfly Therapeutics, Roivant Sciences

CRISPR Therapeutics will develop novel immune-oncology therapies after entering an agreement to use MaxCyte’s cell engineering platform. The partnership is an...Read More... The post Deals this week: CRISPR, Dragonfly Therapeutics, Roivant Sciences appeared first on Drug Development Technology.

Deals this week: Voyager Therapeutics, Pulmatrix, Horizon Discovery

Voyager Therapeutics will develop and commercialise Neurocrine Biosciences’ gene therapy candidates used to treat severe neurological conditions after a collaboration was...Read More... The post Deals this week: Voyager Therapeutics, Pulmatrix, Horizon Discovery appeared first on Drug Development Technology.

5 Top Weekly NASDAQ Biotech Stocks: Index Up During JPM Week

Axsome Therapeutics, Checkpoint Therapeutics, Bellerophon Therapeutics, Enochian Bioscience and Equillium were last week's top gainers. The post 5 Top Weekly NASDAQ Biotech Stocks: Index Up During JPM Week appeared first on Investing News Network.

Roche kauft US-Biotechfirma für 4,3 Milliarden Dollar: Das Unternehmen Spark Therapeutics hat sich mit ...

Das Unternehmen Spark Therapeutics hat sich mit einer Gentherapie gegen Hämophilie hervorgetan. Nun greift Pharmariese Roche nach dem Expertenwissen und kauft Spark Therapeutics für eine Milliarden...

Arena Pharmaceuticals Snags $800 Million from United Therapeutics for a Phase III PAH Drug

United Therapeutics bets a significant amount of money on the potential commercialization of ralinepag.

SPR Therapeutics obtains $8M in funding round

A round of Series C financing has pulled in $8 million for SPR Therapeutics.  -More- 

LNC Therapeutics gets IP from Cornell

LNC Therapeutics licensed exclusive rights to Christensenella patents from Cornell University.

Cardiol Therapeutics Releases Video on Pharmaceutical CBD Market

Cardiol Therapeutics Inc. (TSX:CRDL) (OTC:CRTPF) has released a video regarding the progress it has made in development of its pharmaceutical-grade CBD compound.  The post Cardiol Therapeutics Releases Video on Pharmaceutical CBD Market appeared first on Investing News Network.

BriaCell Therapeutics announces positive proof of concept data in treating breast cancer

Briacell Therapeutics Corp. (OTCQB: BCTXF; TSX: BCT.V) CEO William Williams speaks with Proactive Investor's Christine Corrado at the MicroCap Conference in New York. BriaCell Therapeutics Corp. is an immuno-oncology company which develops immunotherapy treatments for cancer. BriaCell is currently focused on the clinical development of Bria-IMT™ as a 2nd line treatment for patients with adva...

e-Therapeutics (ETX) - Keeping the faith

Edison Investment Research - Pharmaceutical & healthcare - e-Therapeutics: e-Therapeutics’ (ETX) H118 results were a routine financial update highlighting its continuing focus on partnering the Network-driven Drug Discovery (NDD) platform, out-licensing its NDD-derived preclinical immunoncology (I/O) assets and financial prudence. The H118 operating loss was £2.8m. Cash outflow was &po...

Horizon Pharma and HemoShear Therapeutics Enter Exclusive Drug Discovery Collaboration in Gout

DUBLIN & CHARLOTTESVILLE, Va.–(BUSINESS WIRE)–Horizon Pharma plc (Nasdaq: HZNP) and HemoShear Therapeutics, LLC, a privately held biotechnology company, today announced a collaboration to discover and develop novel therapeutics for gout. “As we continue to grow our pipeline, we are committed to addressing unmet treatment needs for people with gout as well as solidifying our leade...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks